Biogen found itself at the center of controversy late last year as it worked with the FDA to grease the wheels for its controversial Alzheimer’s med aducanumab. That back and forth led to accusations the agency wasn’t being impartial in its review — consider the question of whether the drug even works — but for Biogen CEO Michel Vounatsos, controversy proved lucrative.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,